Colorectal cancers (CRCs) with oncogenic mutations in RAS and BRAF are associated with anti-EGFR therapy resistance. Consequently, all RAS mutant CRC patients are being excluded from this therapy. However, heterogeneity in drug response has been reported between RAS mutant CRC patients. It is poorly understood to what extent such differences are derived from different genetic backgrounds or intrinsic differences between the various RAS pathway mutations. Therefore, using CRISPR technology we generated an isogenic panel of patientderived CRC organoids with various RAS pathway mutations (i.e. KRAS G12D , BRAF V600E , KRAS G13D and NRAS G12D ). All RAS pathway mutants promote ERK activation and tumor growth. However, KRAS G12D and BRAF V600E mutations in particular conferred robust resistance to anti-EGFR therapy, both in vitro and in vivo. Moreover, untreated KRAS G13D mutants showed fastest growth in mice but remained sensitive to anti-EGFR therapy. Together, introducing mutationspecific oncogene signaling in CRC organoids resembles clinical phenotypes and improves understanding of genotype-phenotype correlations.
Introduction
The EGFR-RAS signaling pathway stimulates cellular proliferation during development, homeostasis and regeneration 1, 2 . Consequently, aberrant activation of the signaling cascade by oncogenic mutations is frequently detected in cancers 3 . In metastatic colorectal cancer (mCRC), most abundant are mutations in RAS proteins or downstream kinase BRAF and to lesser extent at the receptor level 4, 5 . KRAS, NRAS and HRAS are three RAS isoforms that propagate upstream EGFR signaling activity towards downstream RAF kinases 6 . Despite their ubiquitous expression pattern 7, 8 and high similarity in amino acid sequence (80%) [9] [10] [11] , the prevalence of oncogenic mutations across RAS isoforms are not equally distributed between different cancers 12 . Colorectal cancer is one of the most extreme cases, with mutations in KRAS being detected in 35-50% of the cases 13 , including even distribution across all tumorigenic stages 14 . In contrast, mutations in NRAS are only identified in 3-5% of mCRC patients and predominantly in malignant CRCs [13] [14] [15] , while HRAS mutations are virtual absent 12 . Moreover, the relative mutation frequency at hotspot locations differs between RAS isoforms, with G12 and G13 mutations most often detected in KRAS (combined 90%) and Q61 mutations frequently found in NRAS (57%) 16 . These observations suggest that oncogenic variants of RAS isoforms are not equal during CRC development, including codon-specific influences. Indeed, mouse studies have demonstrated that the endogenous expression of KRAS G12D , but not NRAS G12D , promotes progression of intestinal neoplasia 17 . An increasing amount of observations seem at odds with the almost uniform classification of CRC tumors with a mutant EGFR signaling pathway. Accurate patient stratification based on RAS mutations is clinically relevant given that anti-EGFR targeted therapy has shown beneficial effects in mCRC patients without oncogenic RAS mutations 18, 19 . However, just like oncogenic RAS variants being associated with different tumor phenotypes, various clinical studies demonstrated differences in therapeutic outcome for mCRC patients with different oncogenic RAS variants. For instance, they reported that mCRCs with KRAS codon 13 mutations are more often associated with a poorer prognosis compared to those with KRAS codon 12 mutations [20] [21] [22] . Paradoxically, patients with KRAS codon 13 mutations are reported to benefit from treatment with EGFR inhibitors [20] [21] [22] , in contrast to resistant KRAS codon 12 mutant tumors. Unfortunately, the cause and consequences of potential differences between these oncogenic variants are poorly understood. In particular, intrinsic differences in tumorigenic potential between mutant variants is challenging to dissect, considering the immense different mutational backgrounds per human tumor 5 . Moreover, NRAS mutations are more often detected in tumors of the left colon, whereas KRAS mutant tumors are most frequently found in right colon 14, 23 , creating the possibility that these are two different tumor subtypes of different epigenetic make-up and cellular composition. The situation is even more extreme for oncogenic mutations in BRAF (mostly V600E) that are detected in approximately 11% of CRC cases 4 . In contrast to RAS mutations, BRAF mutations are common in tumors with a hypermutation phenotype (microsatellite unstable) 24 , show co-occurrence with WNT pathway mutations in RNF43 rather than in APC 4, 5 and show different metastatic behavior 16, 23 . To optimize personalized cancer treatment of CRC patients, we set out to improve our understanding of genotype-phenotype correlations and investigate the intrinsic similarities and differences between a series of common mutations in the EGFR signaling pathway. Patient-derived CRC organoids (CRC PDOs) are 3-dimensional 'mini-organs' that are established from primary tumor tissue, either obtained from biopsies or surgical resected material. CRC PDOs maintain the histopathological features of the native tumor, including high concordance between somatic mutations, transcriptome and drug response between matched primary tumors and derived organoid cultures [25] [26] [27] . Importantly, PDOs are compatible with CRISPR/Cas9-mediated introduction of cancer mutations 28, 29 , and were used to generate a series of isogenic lines with various oncogenic RAS pathway mutations to reveal their similarities and differences.
Results

CRC PDOs with different MAPK pathway mutations display varying sensitivities to MAPK pathway inhibition
To document the intertumoral heterogeneity in drug response between CRCs with an oncogenic mutant MAPK signaling pathway, we performed a drug screen targeting various effectors in the MAPK pathway ( Fig. 1A and B ). Specifically, we applied this screen on a panel of CRC PDOs that are either wild-type or mutant for KRAS, NRAS or BRAF without displaying any other MAPK pathway mutations detected by Sanger sequencing (Suppl. Fig. 1A ).
In line with observations from the clinic, we observed that CRC PDOs with activating mutations in RAS and BRAF exhibited resistance to the pan-HER inhibitor afatinib 18, 30, 31 . The strongest sensitivity to pan-HER inhibition was observed in two out of the four RAS/BRAF WT CRC PDOs (P18T and B2-071) ( Fig. 1C and Suppl. Fig. 1B) . We noticed limited response to pan-HER inhibition in the two remaining RAS/BRAF WT CRC PDOs (B2-054 and B2-074). Potentially, these CRCs have MAPK pathway alterations that are either unknown, or were not identified by Sanger sequencing 29, [32] [33] [34] , but are in agreement with clinical observation of CRC patients enrolled in anti-EGFR therapy that show no response 35 . In concordance with previous clinical and experimental observations, MAPK pathway inhibition downstream of RAS and BRAF with only the MEK inhibitor selumetinib was largely ineffective in the panel CRC PDOs [36] [37] [38] (Fig. 1D and Suppl. Fig. 1B ). However, upon combinatorial treatment with both pan-HER and MEK inhibitors, an improved drug response was predominantly detected in Kand NRAS mutant PDOs ( Fig. 1E and Suppl. Fig. 1B) . Treatment with the ERK inhibitor SCH772984 showed the strongest effect on KRAS mutant and RAS/BRAF WT CRC organoids, albeit at varying sensitivities ( Fig. 1F and Suppl. Fig. 1B ). Combinatorial treatment with ERK and MEK inhibitors induced an additive effect in most CRC organoids, irrespective of the mutational background, while variability in response between CRC PDOs remained largely unaffected ( Fig. 1G and Suppl. Fig. 1B) . Response to BRAF inhibition with vemurafenib, largely ineffective in most CRC PDOs including organoids mutant for BRAF, corresponds with previous observations in CRC cell lines and clinical studies [39] [40] [41] [42] (Fig. 1H and Suppl. Fig. 1B) . Strikingly, only a minor additive response was observed when pan-HER and BRAF inhibitors were co-administered in CRC PDOs ( Fig. 1I and Suppl. Fig. 1B) , recapitulating observations from the clinic about insufficient response rates in BRAF mutant patients 43 . Remarkedly, differential drug sensitivities were observed between CRC PDOs with similarly affected oncogenes. In particular the NRAS G12C mutant showed higher sensitivity to most drugs than the other NRAS mutants, either due to the type of point mutation or other tumor intrinsic properties. Similar type of deviation in drug response was observed between KRAS mutants, confirming previous reports on CRC organoid biobanks with various RAS mutants 26, [44] [45] [46] . Overall, BRAF mutant CRC PDOs showed a very resistant phenotype to MAPK pathway inhibition. However, the nature of their primary tumors (e.g. sessile serrated 
Generation of endogenous oncogenic RAS and BRAF knock-in variants in CRC PDOs
To exclude the impact of genetic background, epigenetics and cellular composition on drug response when comparing various oncogenic mutations in the MAPK pathway, we set out to generate a panel of isogenic CRC PDOs harboring different RAS pathway mutations (RPMs). Apart from a non-functional APC and TP53 pathway, CRC PDO P18T has a genetically wild-type MAPK signaling pathway and shows sensitivity towards EGF-mediated tumor growth ( Fig. 1C and Suppl. Fig. 1B ) 25 . Therefore, we isolated CRC PDO P18T to introduce different oncogenic mutations in KRAS, NRAS and BRAF via homologous recombination (HR) using the CRISPR technology ( Fig. 2A) . Importantly, the donor template contained a puromycin selection cassette to enable selection independent of using the attributed mutant phenotype for selection like previously applied growth factor depletion regimens (e.g. EGF) ( Fig. 2A and  2B) 47, 48 . Next, we targeted CRISPR/Cas9 to the intronic region directly downstream of the exon of interest. Although this position is not optimal in relation to the distant upstream location of the point mutations, introducing a small intronic indel mutation in the non-recombined allele will have minimal to no impact on its integrity. Maintaining the expression of the wildtype allele is essential as it avoids allelic imbalance, a phenomenon that has been described during progression to malignancy where mutant KRAS gains the upper hand over wild-type [49] [50] [51] [52] (Fig. 2A) . The generation of oncogenic mutations in KRAS, NRAS and BRAF were confirmed by DNA sequencing analysis of three independent monoclonal lines ( Fig. 2C) , confirming the presence of both mutant and wild-type alleles. Additional DNA sequence analyses of the intronic regions targeted by Cas9 confirmed the generation of indels in the allele that was not subjected to HR (Suppl . Fig 2A and 2B) . In agreement, both wild-type and mutant alleles were shown to be expressed at near equal ratios in the isogenic RPM lines as demonstrated by qPCR analysis using allele-specific primers (Fig. 2C) . Subsequent RAS-GTP pull down assays with the RAS binding domain (RBD) of RAF confirmed presence of oncogenic RAS proteins, including overall correlation between increased active RAS-GTP loading levels and mRNA expression of the mutant allele ( Fig. 2D) . Moreover, we observed increased protein levels of total RAS in RAS mutant organoids, indicative of positive feedback regulation induced by oncogenic RAS proteins as previously reported [53] [54] [55] .
Figure 2. Generation of oncogenic BRAF and RAS knock-in variants in CRC PDOs.
(A) Genetic strategy to target KRAS, NRAS and BRAF locus for homologous directed repair using CRISPR/Cas9 technology. Red and blue lines indicate oncogenic missense and silent mutations, respectively. Black boxes illustrate exons, separated by introns. Red scissor shows sgRNA-generated double stranded break. Black arrows illustrate PCR primer pairs that were used for the identification of knock-in clones. (B) Puromycin selection strategy to generate RAS and BRAF mutant CRC PDOs after CRISPR-mediated homologous recombination. (C) Per mutation the agarose electrophoresis gels showing the ~1kb PCR product of the knock-in allele in 3 monoclonal lines per mutations. Sanger sequencing confirms presence of both knock-in and WT alleles. DNA sequences show introduction of missense (red) and silent (blue) mutations. The mRNA expression levels of wild-type and mutant alleles was analyzed using qPCR. The relative expression of each allele was normalized to the B2M housekeeping gene (representative from n = 3 independent experiments). (D) Western blot analysis shows enhanced RAS activity (GTP-loading) in RAS mutant CRC PDOs compared to P18T organoids. KRAS and NRAS immunoblots from RAS pull-down assays (RAS-GTP) and total lysates (loading control) are shown for KRAS and NRAS mutant organoids, respectively. Representative from n=2 independent experiments.
BRAF V600E and KRAS G12D knock-in CRC PDOs show resistance to pan-HER inhibition
To maintain clonal diversity, we continued with three independent clones per oncogenic mutation and investigated their effect on EGF-dependent tumor growth. Therefore, we monitored organoid number, size, and viability at different time points after organoid plating and drug administration (Suppl. Fig 3A) . Under normal growth conditions, we observed no significant differences between parental P18T and oncogenic RPM lines ( Fig.  3A) . However, significant differences were observed when we challenged the RPM organoids with the pan-HER inhibitor afatinib to block all EGF-stimulated receptor signaling. Whereas all oncogenic RPM organoids had a survival benefit compared to parental P18T organoids upon short-term (3 days) afatinib treatment, organoids expressing KRAS G12D and BRAF V600E oncogenes showed most resistance to afatinib that became most prevalent during long-term (7 days) treatment ( Fig. 3B and Suppl Fig. 3B ). In particular, relapse after drug treatment showed a striking growth of both KRAS G12D and BRAF V600E mutant organoids, while the others were significantly depleted in number or showed growth arrest ( Fig. 3C-D and Suppl. Fig. 3C ). While overall phenotypes per mutation showed resemblance, we did observe interclonal heterogeneity, in particular for NRAS. Presumably epigenetic and/or transcriptional differences between the cells-of-origin of the mutant clones can still affect phenotype 26, 45 . For example, the most resistant NRAS G12D clone (#1) correlates with highest expression level and GTP-loading of the mutant protein ( Fig. 2C and 2D) . Remarkedly, regardless of oncogenic RAS pathway mutations, we observed that growth remains dependent on additional HER-mediated signaling input ( Fig. 3B and D) . Although the HER receptor family is upregulated in the RPM organoids (Suppl. Fig. 3D ), we noticed that EGFR signaling was mostly responsible for this (Suppl. Fig. 3E ). . Each dot represents one organoid 76 . Data from 1 8-well Lab-Tek chambered coverglass is shown. (B) Representative fluorescent pictures of parental P18T, or KRAS G12D , KRAS G13D , NRAS G12D and BRAF V600E knock-in organoids (clone # 1) after 7 days of DMSO or afatinib treatment (1 µM). Scale bars, 100 µM. Hoechst (blue) and DRAQ7 (red) was used to visualize nuclei and dead cells, respectively. (C) Representative bright field pictures of parental P18T, or KRAS G12D , KRAS G13D , NRAS G12D and BRAF V600E knock-in organoids (clone # 1) 7 days after release of afatinib treatment (day 14). Representative zoomin panels show fluorescent calcein green signal in living cells. Asterisks indicate autofluorescence of dead material (Suppl. Fig 3C) . (D) Quantitative analysis of organoid growth and viability in isogenic RPM lines prior (day 0), during (day 7) and after (day 14) treatment with afatinib (1 µM). Size and number of viable organoids were measured by uptake of fluorescent calcein green (see methods). Each dot represents one organoid 76 . Data from 1 8-well Lab-Tek chambered coverglass is shown.
BRAF V600E and KRAS G12D knock-in CRC PDOs show residual MAPK pathway activation upon pan-HER inhibition
Previous studies have indicated that the lack of sensitivity towards MAPK pathway inhibition in RAS and BRAF mutant CRCs is caused by residual levels of ERK activity 41, 56, 57 . To investigate the molecular mechanism underlying resistance to pan-HER inhibition as observed in KRAS G12D and BRAF V600E RPM organoids, we analyzed MAPK signaling activity using biochemistry. As expected, introduction of the oncogenic mutations in RPM organoids resulted in increased ERK activation under normal culture conditions ( Fig. 4A, Suppl. Fig. 4A ). In line with the sensitive phenotypes during pan-HER inhibition, we noticed complete loss of MEK and ERK activity in P18T organoids as well as in KRAS G13D and NRAS G12D RPM organoids. In contrast, residual MEK and ERK activity was observed in RPM organoids expressing KRAS G12D and BRAF V600E , albeit with different kinetics (Fig. 4A, Suppl. Fig. 4A ). Initially, all organoids with oncogenic RAS variants displayed a fast and full inhibition of ERK phosphorylation upon pan-HER inhibition. Subsequently, over the course of 24 hours most reactivation of ERK was observed in the presence of mutant KRAS G12D . Unlike oncogenic RAS variants, the drug response of BRAF V600E mutant organoids towards pan-HER inhibition displayed slower kinetics of downstream pathway inhibition (Fig. 4A, Suppl. Fig. 4A ). Moreover, even after 72 hours we noticed no strong reactivation of ERK as consistently observed in KRAS G12D organoids, but minimal levels that remained stable over time (Suppl. Fig. 4B) . Notably, the minimal levels of ERK phosphorylation observed after 24 hours of pan-HER inhibition in BRAF V600E mutants seem comparable to KRAS G13D organoids ( Fig. 4A, Suppl. Fig. 4A ), but their sensitivity towards pan-HER inhibition deviates substantially ( Fig. 3B-D) . This suggests that minimal differences in ERK activity at the lower range can induce different cellular effects. The level of active RAS-GTP was elevated in almost all RAS mutant RPM organoids in unperturbed culture conditions ( Fig. 4B and Suppl. Fig. 4C-D) with the exception of NRAS G12D # 2, which is consistent with the limited expression levels of the mutant allele. Subsequently, an overall decrease in RAS-GTP loading was observed for all mutant lines in the absence of upstream EGFR signaling input, although the degree of reduction varied per mutation (least in KRAS G12D , most in KRAS G13D ) and per clone. shows sustained ERK and MEK phosphorylation in KRAS G12D and BRAF V600E organoids compared to P18T, KRAS G13D and NRAS G12D organoids. Top panels are representative biochemistry experiments on clone # 1 from n=3. Bottom scatter plot depicts ERK phosphorylation levels normalized to GAPDH for all clones (n>4). Baseline of P18T (DMSO) is set at 1. (B) Top panels depict biochemistry on RAS activity (GTP-loading) in unperturbed culture conditions and pan-HER inhibition (1 µM afatinib) for KRAS (G12D and G13D) and NRAS (G12D) mutant clones # 1 and 2 compared to P18T CRC organoids. RAS immunoblots from RAS pull-down assay are shown (RAS-GTP), together with a RAS immunoblot from total cell lysates as loading control. HRAS, KRAS, and NRAS isoforms are detected in mutant KRAS pull-down assays. NRAS isoforms are detected in mutant NRAS pull-down assays. Representative from n = 3 independent experiments. Scatter plots below depict RAS-GTP levels normalized to GAPDH for all clones (n>3). Baseline of P18T (DMSO) is set at 1.
Interclonal variability on karyotype and transcriptome
All RPM clones were created from the same polyclonal P18T organoid culture. As a result, clonal RPM lines can originate from different subclones present in the parental culture and might underly interclonal variability. To interrogate the clonal origin of the RPM lines, we determined DNA copy number alterations (CNAs) of the RPM organoids to determine clonalspecific karyotypes. Overall, a high degree of similarity in the pattern of CNAs was observed across all isogenic RPM organoid lines and the parental P18T organoids (Fig. 5A) . Moreover, amplification of the BRAF allele as indicated in the CNA plots, corresponds with the detection of two wild-type alleles with independent Cas9-created indels in BRAF V600E # 1 (Suppl. Fig. 2B) .
Notably, RPM clones with the highest passage numbers (clone #1, passage number data not shown) showed most extreme deviations from the average karyotype, indicative of ongoing clonal evolution during culture as previously reported 26 . In addition to ongoing chromosomal instability, certain clones displayed a higher degree of CNA resemblance than to others. In particular, a gain of chromosome 2 in half of the clones and (sub)chromosomal loss of chromosome 4 in most but not all. The observed gross similarities in karyotypes is likely the result of monoclonal lines originating from different clonal populations that were present in the polyclonal bulk P18T culture. In particular, NRAS G12D # 1 that is the most phenotypic outlier of the NRAS G12D mutants also displays most genomic alterations, potentially supporting the concept that clonal origin may underly interclonal variability. Nevertheless, overall phenotypic response towards EGF-independent growth conditions seems primarily dictated by the specific RAS pathway mutation and independent of clonal deviations. Next, we performed RNA sequencing analysis to investigate the degree of clonal variability on the transcriptional level, both during normal growth conditions as well as during pan-HER targeted therapy. To measure the variance in global gene expression between all RPM lines, we performed Principle Component Analysis (PCA, Methods). Based on the first two principle components, the largest differences in gene expression were observed between DMSO and afatinib treated conditions and between wild-type and mutant RAS pathway organoids (Fig.  5B) . Moreover, during normal growth conditions we noticed somewhat random clustering between all RPM clones, but a tendency to cluster per mutation/phenotype during EGFdeprived signaling with KRAS G12D and BRAF V600E clustering towards the center of the PC1 axis. Subsequently, we determined the transcriptional signature mediated by EGFR signaling in CRC organoids in relation to RAS/RAF oncogene-mediated transcriptional activity. Using the parental P18T organoids with a wild-type MAPK pathway, we identified the EGFR gene signature by perturbing receptor activity using pan-HER inhibition (266 differentially expressed genes) (Suppl. Fig. 5A and Suppl. Table 1 ). Intriguingly, this EGFR gene signature with many known targets of the MAPK pathway remains to a large extent dependent on upstream EGFR signaling activity in the RPM mutants (Fig. 5C, Suppl. Fig. 5A and Suppl. Table  1 ), in agreement with the significant reduction in ERK activity upon afatinib treatment. Target genes of the EGFR signature that are least affected in the RPM mutants relate to cell cycle pathways, which is most dramatic for KRAS G12D and BRAF V600E RPM lines and in line with the 
Intertumoral heterogeneity between MAPK oncogenic mutations during drug responses
To improve the characterization of drug response phenotypes in relation to KRAS, NRAS and BRAF oncogenes, we performed a drug screen on the RPM organoids with various targeted inhibitors against the MAPK pathway ( Fig. 6A) . Confirming previous observations, KRAS G12D and BRAF V600E RPM organoids showed resistance to pan-HER inhibition with afatinib, with NRAS G12D mutants being an intermediate and KRAS G13D phenocopying the parental P18T line ( Fig. 6B and Suppl. Fig. 6A ). While MEK inhibition alone showed limited effect, intertumoral variability was as expected ( Fig. 6C and Suppl. Fig. 6A ). Moreover, combined inhibition of MEK and pan-HER showed high sensitivity for P18T, KRAS G13D and NRAS G12D mutant organoids, with a pronounced additive effect on NRAS G12D organoids ( Fig. 6D and Suppl. Fig. 6A ). Monotherapy against ERK with SCH772984 showed a similar pattern as MEK inhibition, albeit with overall lower IC50s ( Fig.  6E and Suppl. Fig. 6A ), while intertumoral variability in drug response upon combining MEK and ERK inhibitors resembled pathway inhibition via pan-HER and MEK inhibition ( Fig. 6F and  Suppl. Fig. 6A ). General insensitivity towards BRAF inhibition with vemurafenib was observed in all RPM organoids, including BRAF V600E (Fig. 6G and Suppl. Fig. 6A ), with minimal additive effects upon its combination with dominant pan-HER inhibition ( Fig. 6H and Suppl. Fig. 6A) . Together, the data confirm earlier observations that KRAS G12D and BRAF V600E impose a more resistant phenotype towards EGF-independent growth conditions than KRAS G13D and NRAS G12D . In addition, unique targetable vulnerabilities per mutation type were not identified within the MAPK pathway. Next, we decided to focus on multiple patient-derived BRAF V600E mutants (CRC PDOs and BRAF V600E RPMs) in order to keep the oncogenic mutation a constant, while varying between separate tumors. The 3-day drug response phenotypes of BRAF V600E RPM lines showed overall high resemblance to the other BRAF mutant CRC PDOs. Yet, intertumoral heterogeneity was observed between the lines where B2-040 showed most sensitive phenotypes. This confirms the widely supported notion that differences beyond the oncogenic mutation, among others differences in (epi)genetic landscape, cellular composition and transcriptional levels, will additionally impact tumor cell intrinsic drug sensitivities (Suppl. Fig. 6B-I) . 
In vivo tumor growth and response to anti-EGFR therapy
To characterize the similarities and differences of the RPM lines in vivo, we xenografted the RPM organoids in mice to analyze growth dynamics (Fig. 7A) . As expected, tumors from isogenic RPM organoids displayed faster growth rates as compared to the parental P18T organoids (Fig. 7B) . Moreover, we observed that KRAS G13D mutant tumors showed the fastest growth rates compared to other RPM tumors, resembling elevated tumor growth dynamics of mCRC patients with KRAS G13D mutations [20] [21] [22] . More surprising to us was that KRAS G12D showed slowest growth kinetics of the RPM lines, since endogenous expression of KRAS G12D , but not NRAS G12D , promotes cancer progression in murine colonic epithelium after loss of APC expression 17 .
Multiple studies have been published reporting the accuracy of tumor-derived organoids in predicting patient responses to therapy 27, 58, 59 . To verify whether our observed intertumoral differences in drug responses between the RPM lines are also observed in vivo, we applied afatinib treatment for 28 days. Consistent with results from in vitro experiments, a significant decrease in growth rate was observed in P18T, KRAS G13D and NRAS G12D mutant tumors upon afatinib treatment (Fig. 7C-E) . In comparison, BRAF V600E and KRAS G12D mutant tumors were most resistant, showing only a marginal reduction in tumor growth compared to vehicle (Fig.  7 F-G) . Although overall in vitro responses were more dramatic, presumably due to a mismatch between achieved drug concentrations in vivo, the overall pattern of intertumoral differences between the RPM clones remained present. KRAS G13D mutant tumors are an interesting outlier, considering its malignant nature during unperturbed growth conditions in mice. Yet, sensitivity to anti-EGFR therapy remains, so suppressed growth rates could be established towards the range of vehicle-treated parental P18T tumors (Fig. 7D) . This corresponds to observations from the clinic, showing that patients with KRAS G13D mutant CRCs benefit from cetuximab treatment, but are inferior to the response of CRC patients with RAS WT tumors 20,22,60 . 
Discussion
Despite the overlapping functions of RAS and BRAF oncogenes, data analyses of CRC patients and cell lines suggest that mutation variants of oncogenic RAS and BRAF proteins are associated with different tumor types and involved in distinct tumorigenic pathways 17, 23, 61, 62 . Moreover, CRCs with oncogenic RAS variants can react differently to pan-HER inhibition [20] [21] [22] 63, 64 . Nevertheless, stratification of patient cohorts per mutation is significantly hampered by limited statistical power due to small sample sizes. Therefore, mCRC patients with any activating mutation in RAS are currently being excluded from anti-EGFR targeted therapy 65 . Moreover, from a practical point of view it is very challenging to dissect similarities and differences between various oncogenic RAS and BRAF variants using patient-derived material. Foremost, because intertumoral heterogeneity is to a large extent influenced by differences in genetic landscape of the tumor, epigenetics, cellular composition, tumor location, stroma infiltration, and more 4, 23, 24, 62, 66 . Therefore, to address the influence of a single RAS pathway mutation on tumor progression and anti-EGFR therapy resistance, we generated a panel of isogenic CRC PDO lines with endogenous expression of a variety of oncogenic BRAF and RAS mutations. Confirming the oncogenic role of MAPK pathway mutations, we observed that activating mutations in BRAF (i.e. V600E), KRAS (i.e. G12D and G13D) and NRAS (i.e. G12D) enhanced downstream MAPK pathway activity. In the presence of exogenous EGF levels during normal culture conditions, growth analysis and RNA sequencing did not reveal significant differences between the RPM lines. In contrast, under more challenging conditions as EGF-independent growth due to pan-HER inhibition, we noticed apparent differences between the RPM mutants where KRAS G12D and BRAF V600E showed most resistant phenotypes. Same differential sensitivity towards pan-HER inhibition was also observed in vivo. During normal growth conditions in vivo where EGF supply is limited but not absent, KRAS G13D RPM lines displayed enhanced tumor growth over the other RPM tumors. This corresponds to the malignant nature of KRAS G13D mutant CRCs in patients that is likely caused by the high level of intrinsic GDP-to-GTP exchange rates of KRAS G13D mutant proteins, resulting in guanine nucleotide exchange factor (GEF) independent RAS auto-activation 20, 22, 60, 67, 68 . The codonspecific effects of KRAS G13D mutants are likely masked in ex vivo culture conditions with EGF concentrations that saturate EGFR phosphorylation and downstream pathway activation. The structural differences between KRAS G12D and KRAS G13D proteins might explain their distinct response to pan-HER inhibition 68, 69 , as KRAS G13D , but not KRAS G12D , retain sensitivity to GAPmediated GTP hydrolysis as demonstrated by in vitro GTP hydrolysis experiments 67, 68 . The high prevalence of codon 12 and 61 mutations in KRAS and NRAS, respectively, suggests that the transforming capacity differs per oncogenic mutation and RAS isoform 6 (COSMIC database). We observed that NRAS G12D were 'weaker' mutants than KRAS G12D in terms of EGFindependent growth phenotypes of our RPM lines. In contrast, a NRAS Q61 mutant CRC PDO showed most resemblance to KRAS G12D . It has been reported that NRAS codon 61 mutants are more efficient inducers of downstream MAPK signaling than NRAS codon 12 70 . We observed fewer active RAS proteins in NRAS G12D RPM organoids compared to KRAS G12D RPM organoids. A possible explanation for the preference of codon 61 mutations over codon 12 in NRAS is that lower expression levels require compensation by a potent mutation in order to achieve sufficient MAPK activation and transformative capacity. For KRAS, codon 61 mutations might create too much oncogenic potency, as KRAS Q61 mutations appear more active than KRAS G12D mutations in vitro, and result in growth arrest of primary lung fibroblast 50, 71 . Although KRAS G12D and BRAF V600E RPM organoids showed resistance to pan-HER inhibition, a strong reduction in ERK activation and cell proliferation was observed. This indicates that upstream receptor activation is important to elevate levels of ERK activity, despite presence of MAPK pathway activating mutations. Conceptually, this parallels other observations in RAS mutant cancer cells, showing that the capacity of RAS and RAF oncogenes to activate downstream MAPK signaling is not maximal 72, 73 . Moreover, the residual levels of RAS-ERK activity in RAS mutant organoids during drug screens did correlate with observed phenotypes, where ERK phosphorylation levels were significantly higher in afatinib-resistant (KRAS G12D ) clones compared to afatinib-sensitive (KRAS G13D and NRAS G12D ) clones. In contrast, BRAF V600E mutant clones showed a different drug response with respect to ERK phosphorylation than the oncogenic RAS variants, with slower kinetics and an incomplete inhibition but stable suppression over time. Considering that both the KRAS G12D and BRAF V600E mutant organoids manifest similar resistance phenotypes, we speculate that both drug response kinetics, i.e. either suppressed and sustained over time or initially eliminated with subsequent minimal reactivation, effectuate low ERK activity levels that are sufficient to support organoid survival, but not growth. Intriguing, while the minimal levels of ERK activity in BRAF V600E and KRAS G13D mutant organoids seem comparable, their phenotypes deviate significantly. Most likely, minimal differences in ERK activity levels at the lower range might have different phenotypic outcomes. Future methodologies for sensitive quantifications of signaling activities at the single cell level and in real-time will prove instrumental for full understanding how pathway activity levels in tumors correlate with drug response phenotypes (manuscript in preparation), among others to discriminate between heterogeneities of signaling activities between cells and fluctuating activity levels over time. Together, we show that oncogenic knock-in mutations in the MAPK pathway in CRC PDOs resemble phenotypes observed in the clinic and can be used to understand mutation-specific oncogene signaling in CRC. Furthermore, we observed differential sensitivities to MAPK pathway inhibition between RAS pathway mutations, supportive of the notion that mCRC patients with NRAS G12D and KRAS G13D mutations, which are currently being excluded from anti-EGFR targeted therapy, might actually benefit from anti-EGFR therapy. Further investigation will be required to determine whether the current stratification of mCRC patients based on overall RAS mutant status should be reconsidered and include codon-and isoform-specific variations. Indeed, in addition to intrinsic differences between various mutations as revealed with the RPM organoids, cross-comparison of different CRC PDOs with identical BRAF V600E mutation displayed intertumoral heterogeneity beyond the exact mutation type, like genetic landscape, epigenetics, cellular composition, tumor location and stroma infiltration. How all these multiple variables, including mutation type, act in concert in establishing a (drug response) phenotype is challenging to dissect as tumors have often adapted in multiple possible scenarios to accomplice sufficient MAPK activity. Future decision-making for therapeutic strategy should use the most optimal genotype-phenotype correlations to assist in overall patient stratification to narrow down on potential therapeutic options, after which tailored-made adjustments can be made based on personalized drug response data.
Materials and methods
Patient-derived organoid culture and maintenance
The patient-derived P6T, P16T, P18T and P25T organoids used in this study were previously established and characterized 25 . Other patient-derived organoids described in this study were established and characterized by the Hubrecht Organoid Technology (hub4organoids.eu). Human CRC organoids were cultured as described previously 25, 44 . Culture medium contained advanced DMEM/F12 medium (Invitrogen) with 1% Penicillin/Streptomycin (P/S, Lonza), 1% Hepes buffer (Invitrogen) and 1% Glutamax (Invitrogen), 10% R-spondin conditioned medium, 10% Noggin conditioned medium, 1x B27 (Invitrogen), 1.25 mM n-Acetyl Cysteine (Sigma-Aldrich), 10 mM Nicotinamide (Sigma-Aldrich), 50 ng/ml EGF (Invitrogen), 500 nM A83-01 (Tocris), 10 µM SB202190 (ApexBio) and 100 µg/ml Primorcin (Invitrogen). Organoids were splitted through Trypsin-EDTA (Sigma-Aldrich) treatment. Culture medium after splitting was supplemented with 10 µM Y-27632 dihydrochloride. For selection of RAS pathway mutants, organoids were grown in culture medium containing 1-2 µM puromycin.
Organoid transfection and genotyping
The transfection protocol of P18T organoids was previously described in detail by Fujii et al. (2015) . Three days after transfection, culture media plus Y-27632 was exchanged with selection medium. After puromycin selection, surviving clones were picked and subjected to genotyping to detect the presence of homologous recombination. For genotyping, genomic DNA was isolated using Viagen Direct PCR (Viagen). The presence of oncogenic and silent mutations in exons and insertions or deletions in introns of BRAF, KRAS and NRAS was verified by using the PCR product obtained using the following primers:
Phenotypic drug screen and Calcein Green Assay Five days after organoid trypsinization, 1 mg/ml dispase II (Invitrogen) was added to the medium of the organoids and these were incubated for 15 min at 37° C to digest the BME. Subsequently, organoids were mechanically dissociated by pipetting, filtrated using a 40 µm nylon cell strainer (Falcon), resuspended in 75% BME/growth medium (40 organoids/µl) prior plating of two 10 µl drops on Nunc TM Lab-Tek TM II Chamber Slide TM Systems. After plating culture medium containing either 1 µM of afatinib, 1 µM of erlotinib or DMSO was added. The labtek plates were mounted on an inverted confocal laser scanning microscope (Leica SP8X) and imaged using a 10X objective. For visualization of cell viability, organoids were incubated with 16.2 µM Hoechst 33342 (Life Technologies) and 1.5 µM DRAQ7 TM (Cell Signaling #7406) for 30 min at 37° C prior imaging. For calculating organoid viability, the morphology of 100 organoids was scored after 3 and 7 days of 1 µM afatinib (pan-HERi) treatment. For organoid viability and growth analysis, organoids were imaged by an inverted routine microscope (Nikon Eclipse TS100) using a 4X objective. For calculating organoid count and size, organoids were incubated for 20 minutes with 500 ml culture medium containing 5 µM calcein-green (Invitrogen). For the quantification of the organoid size and count, FIJI analysis software was used and presented as dot plots 74 .
Drug screen and viability assessment
Five days after organoid trypsinization to single cells, 1 mg/ml dispase II (Invitrogen) was added to the medium of the organoids and these were incubated for 15 min at 37° C to digest the BME. Subsequently, organoids were mechanically dissociated from the BME by subtle pipetting, filtrated using a 40 µm nylon cell strainer (Falcon), resuspended in 2% BME/growth medium (15-20,000 organoids/ml) prior plating of 30 µl (72 hrs drug screen) or 50 µl (7 days drugscreen) (Multi-dropTM Combi Reagent Dispenser) on BME pre-coated 384-well plates. The drugs and their combinations were added 3 hrs after plating the organoids by using the Tecan D300e Digital Dispenser. Drugs were dispensed in a non-randomized manner and DMSO end concentration was 0.9% in all wells. 72 hrs or 7 days after adding the drugs organoids were fixed with 4% PFA (Merck) and stained with Hoechst (Invitrogen). Organoids were screened by automated microscopy of whole wells (CX5 High Content Screening (HCS) platform (Thermo Scientific), equipped with an Olympus UPLFLN U Plan Fluorite 4x Microscope Objective). Organoid roundness was measured by integrating Hoechst signal and contrast using Columbus Cellular imaging and analyses (Perkin Elmer). Relative survival was determined by normalization of the results to DMSO (= 100% alive) and 20 µM Navitoclax (= 0% alive), which induces maximal killing within 72 hours after treatment. Multiple identical drug combinations were averaged.
Targeted inhibitors
Afatinib, Selumetinib, Vemurafenib, Erlotinib and Navitoclax were purchased from Selleck Chemicals. SCH772984 was obtained from MedChem Express. These compounds were dissolved in dimethylsulfoxide (DMSO, Sigma-Aldrich) and stored as 10 mM aliquots.
Curve fitting and drug sensitivity
Dose-response curves were generated using GraphPad software by performing nonlinear regression (curve fit), assuming a standard Hill equation (chosen method: log(inhibitor) vs. Response, constrain top=100).
RNA seq
Organoids were treated with DMSO or afatinib (1 µM) for 24 hours and organoids were lysed in RLT lysis+ buffer containing 1% beta-mercaptoethanol. RNA was extracted with the QiaSymphony SP kit (Qiagen) according to the manufacturer's protocol. RNA-libraries were prepared for sequencing with the Illumina Truseq Stranded mRNA polyA kit and sequenced on the NextSeq500 platform (1x75bp, 20M reads per sample). Data were processed by the UBEC facility Illumina analysis pipeline (https://github.com/UMCUGenetics/RNASeq) by utilizing STAR (v2.4.2a) to map the reads. Samples were normalized for sequencing depth based on the sum of the read counts over all genes for each sample. Expressed genes were selected by excluding all genes where ≥ 3 samples had less than 10 reads. Principal Component Analysis (PCA), Euclidean Distance-based clustering and Differential Expression (DGEA) calculations were performed with the DESeq2 package 75 . P-adjusted (padjusted) was calculated by multiplying the p-value with the number of genes (=expressed genes) tested. Unsupervised hierarchical clustering was performed on all differentially expressed genes. DGEA was performed on untreated parental P18T lines vs. untreated KRAS G12D , KRAS G13D , NRAS G12D and BRAF V600E mutant lines, on treated parental P18T lines vs. treated KRAS G12D , KRAS G13D , NRAS G12D and BRAF V600E mutant lines, on untreated vs treated lines per mutation, or on treated KRAS G12D and BRAF V600E vs KRAS G13D and NRAS G12D mutant lines. For subsequent analysis, we set a cut-off threshold of a log2 2 fold change of genes that were differentially expressed in all three (mutant) or four (P18T) monoclonal lines.
CNAs
Genomic DNA was extracted from the parental P18T and RAS pathway mutant organoid lines using the QIAamp DNA Micro Kit (Qiagen) according to the manufacturer's protocol. Approximately 100 ng genomic DNA of each sample was used for DNA library preparation (TruSeq Nano DNA library preparation kit, Illumina). Subsequently, libraries were sequenced on an Illumina NextSeq500 using 75-bp single-end sequencing. Raw sequencing data was aligned to human reference genome hg19/GRCh37 using Burrows-Wheeler Aligner mapping tool (BWA-MEM; Version 0.7.5a). Further data processing procedures are fully described at: https://github.com/UMCUGenetics/IAP. DNA copy number profiles were generated using Ginkgo as described by Garvin et al. (2015) 76 (pipeline available at: https://github.com/robertaboukhalil/ginkgo). The reads were binned into 1 Mb variablelength intervals and data was segmented to obtain copy number estimates across the genome. Copy number values deviating >0.6 from the average ploidy were considered to indicate deletions or amplifications. R package ggplot2 was used to generate a heatmap for visualization.
Organoid xenograft experiments
Approval for this study was obtained by the local animal experimental committee at The Netherlands Cancer Institute (IVD-NKI; OZP 80102; WP8520). Parental P18T and RAS pathway mutant knock-in patient-derived organoids were transplanted subcutaneous as single cells at a density of 3x10^5 organoids in 100 µl 50% Matrigel/medium with 10% collagen type I (BD Bio-sciences) mixture into NSG-B2m mice (JAX stock no: 010636). Tumor growth dynamics were analyzed for 35 days in mice with established tumors of 50 mm 3 . Mice with established tumors (average volume of 200 mm 3 ) were treated with afatinib (20 mg/kg; five days on, two days off) or vehicle for four weeks. After two weeks recovery from the drug treatment, mice were sacrificed. Tumor volumes were evaluated three times per week by caliper and the approximate volume of the mass was calculated using the formula Dxd2/2, where D is the major tumor axis and d is the minor tumor axis. For in vivo dosing, afatinib was dissolved in 1.8% hydroxypropyl-bcyclodextrin (Sigma), 5% of a 10% acetic acid stock and aqueous natrosol (0,5%). All agents were administered via oral gavage. We used 5 mice per group that were randomly assigned to the different treatment groups before the start of the experiment. We determined outliers with the following rule: If a number is less than Q1-1.5xIQR or greater than Q3+1.5xIQ, then it is considered to be an outlier, with IQR being the interquartile range, equal to the difference between the third quartile (Q3) and first quartile (Q1). Mice that showed outliers in more than 40% of the total number of measurements were excluded from analysis.
Statistical analysis
GraphPad Prism 8.1.1 was used for statistical analysis. All values are given as means + SD, as indicated in figure legends. Comparison between two groups were made by Welch's t-test. For comparison of more than two groups, we used 2-way ANOVA with subsequent Dunnett's or Bonferroni's multiple comparison test.
